News

11 09, 2018

Scientists discover hormone therapy’s impact on prostate cancer

2018-09-11T09:01:12+00:00September 11th, 2018|

Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Prostate cancer is the second-leading cause of cancer death in men, behind lung cancer, killing nearly 30,000 in the U.S. each year, according to the American Cancer Society. In its early stages, the most common type, adenocarcinoma, is curable and generally responds well to therapies, including those that target androgen -- a male sex hormone that stimulates tumor growth. However, in certain patients, the cancer becomes resistant to androgen-targeted therapy, and the cancer recurs or spreads. One possible reason [...]

21 08, 2018

Researchers uncover new way of targeting advanced prostate cancers

2018-08-21T07:45:39+00:00August 21st, 2018|

Certain molecular drivers of cancer growth are "undruggable" -- it's been nearly impossible to develop chemicals that would block their action and prevent cancer growth. Many of these molecules function by passing cancer-promoting information through a gate in the nucleus, where the instructions are carried out. Researchers at the Sidney Kimmel Cancer Center -- Jefferson Health have found a way to block the nuclear gates used by these molecules, and show that this inhibition can halt aggressive prostate cancer in mice bearing human tumors. The research, co-led by Veronica Rodriguez-Bravo, PhD, and Josep Domingo-Domenech, MD, PhD, published in Cell August 9, 2018. "We found that a particular gatekeeper, the nuclear pore protein called POM121, traffics molecules that boost tumor aggressiveness," said first and [...]

7 08, 2018

Eat by 9 p.m. to stave off prostate cancer say researchers

2018-08-07T11:46:52+00:00August 7th, 2018|

Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 pm or wait at least two hours before going to sleep have an approximate 20% lower risk of those types of cancer compared to people who have supper after 10pm or those who eat and go to bed very close afterwards, respectively. These were the main conclusions of a new study by the Barcelona Institute for Global Health (ISGlobal), a center supported by the "la Caixa" Banking Foundation. The study is the first to analyses the association between cancer risk and the timing of meals and [...]

1 08, 2018

Dr. Michael Lazar New Radio Interview on Here’s to Your Health

2018-08-01T08:23:00+00:00August 1st, 2018|

HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised to 90 degrees Celsius, destroying the targeted tissue. Men treated with HIFU wake up and go home without pain or bleeding.  They are able to travel the same day, drive the next day, and resume normal activities within a few days.  Those with office based jobs [...]

17 07, 2018

New Study Shows HIFU for Prostate Cancer Yields Excellent Cancer Control

2018-07-24T09:52:11+00:00July 17th, 2018|

New 5-Year Sonablate® Study Shows Focal HIFU for Prostate Cancer Yields Excellent Cancer Control with Minimal Side Effects HIFU Prostate Services, the largest provider of HIFU Services in US is pleased to announce an Extensive Multicenter Research Study that Demonstrates Sonablate® HIFU Outcomes are Equivalent to Surgery While Maintaining Urinary Continence and Erectile Function Charlotte, N.C. (July 6, 2018) – A 5-year multicenter study following focal therapy for prostate cancer, with the Sonablate HIFU technology, has been published and shows it is possible to achieve whole-gland equivalent cancer control rates without the side effects seen with whole gland treatments. The data demonstrated that focal Sonablate HIFU, or High Intensity Focused Ultrasound, has achieved success rates similar to more traditional prostate cancer surgical procedures [...]

10 07, 2018

New Study: HIFU for prostate cancer as effective as surgery or radiotherapy

2018-07-10T08:20:41+00:00July 10th, 2018|

Using high energy ultrasound beams to destroy prostate cancer tumors may be as effective as surgery or radiotherapy, but with fewer side effects. A new study, carried out at six hospitals across the UK, tracked 625 men with prostate cancer who received a type of treatment called high-intensity focused ultrasound (HIFU). The research, published in the journal European Urology, is the largest ever study of HIFU treatment used to target prostate tumours. The treatment is similar to a 'lumpectomy' for other cancers -- where doctors remove only tumour cells, leaving as much healthy tissue as possible. The findings, from a number of institutions including Imperial College London and University College London, found that after five years the cancer survival rate from HIFU was 100 per [...]

19 06, 2018

Global health insurance company Cigna covers HIFU

2018-06-19T14:59:20+00:00June 19th, 2018|

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center --> Cigna, a a global health insurance service company based in the US, announced earlier this year that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment. In other words, if a man was diagnosed with localized prostate cancer and then had radiation therapy then had the cancer return to the prostate and was diagnosed with localized recurrent prostate cancer, he may be eligible for coverage for having HIFU as a salvage option. It is important to note that coverage is policy specific so it may vary depending on the policy.  More information is available from Cigna [...]

12 06, 2018

It’s Men’s Health Month – A Focus on Prostate Cancer Prevention

2018-06-12T07:40:41+00:00June 12th, 2018|

Is prostate cancer prevention possible? Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. [...]

5 06, 2018

New study reviews PSA screening results following prostate cancer treatment

2018-06-05T11:03:37+00:00June 5th, 2018|

A study assessed whether monitoring prostate cancer patients following treatment with a PSA test every three months versus once a year would provide a long-term survival benefit. Prostate cancer patients who were monitored more frequently after treatment did not live significantly longer than patients who were monitored once a year, according to study findings led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. At the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented findings on Friday, June 1, from an analysis of data from nearly 10,500 prostate cancer patients in the United States from 2005 to 2010. The study's primary goal was to determine if more frequent monitoring with the prostate-specific antigen test after treatment improved patients' [...]

22 05, 2018

Fewer men are being screened, diagnosed, and treated for prostate cancer

2018-05-22T15:07:32+00:00May 22nd, 2018|

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]